Iovance Biotherapeutics 更新企业演示材料并提交 8-K
IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Iovance Biotherapeutics 于 11 月 5 日更新用于医疗保健会议及面向分析师、现有股东等群体的企业演示材料,并提交 Form 8-K。演示文稿作为附件 99.1 纳入文件。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 05, 2026 |
IOVANCE BIOTHERAPEUTICS, INC.
(Exact name of Registrant as Specified in its Charter)
Delaware |
001-36860 |
75-3254381 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
300 Rouse Blvd. |
||||
Philadelphia, Pennsylvania |
19112 |
|||
(Address of Principal Executive Offices) |
(Zip Code) |
|||
Registrant’s Telephone Number, Including Area Code: 650 260-7120 |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Trading |
|
||
Common Stock, par value $0.000041666 |
IOVA |
The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On November 5, 2026, Iovance Biotherapeutics, Inc. (the “Company”) updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit |
Description |
|
99.1 |
Iovance Biotherapeutics, Inc., Corporate Presentation – November 2026 |
|
104 |
Cover Page Interactive Data File (embedded as Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Iovance Biotherapeutics, Inc. |
|||
Date: |
November 5, 2026 |
By: |
/s/ Frederick G. Vogt |
Name: Frederick G. Vogt, Ph.D., J.D. |
来源:SEC EDGAR · 本站存档